Leukemia Clinical Trials in Dallas

Showing 1221-1240 of 1,246 trials

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

NCT00088088

This study is for patients who have Stage IIIb or Stage IV NSCLC and have never had chemotherapy before for their disease. The first phase of the study recently completed and for the second phase of the study patients are randomly assigned to receive either paclitaxel and carboplatin or paclitaxel and carboplatin and study drug (STA 4783). Treatment will be every 3 weeks for 6 cycles.

Stage IIIB Non-Small Cell Lung CancerStage IV Non-Small Cell Lung Cancer

Synta Pharmaceuticals Corp.86 participantsStarted Mar 2004

Jonesboro, Arkansas, United States • Pomona, California, United States • San Francisco, California, United States +16 more locations

TERMINATEDPhase 3< 1 mile

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

NCT00290017

This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.

Carcinoma, Non-Small-Cell LungLung CancerNeoplasms, Lung+1 more

Point Therapeutics400 participantsStarted Feb 2006

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Hot Springs, Arkansas, United States +98 more locations

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Leukemia Trials in Other Cities

Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy

Amonafide in Combination With Cytarabine in Secondary AML

A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned

Safety and Immunogenicity of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small Cell Lung Cancer

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery

Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia

CPG 7909 Injection in Non-Small Cell Lung Cancer

A Multicenter Phase 2 Study of CI-1040 in Patients With Advanced Nonsmall-Cell Lung, Breast, Colon and Pancreatic Cancer

Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide

Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Other Conditions in Dallas